Newsroom

Absci 2d ago

We’re proud to share a recent highlight from our partnership with AMD: a dedicated AMD Instinct™ MI300X cluster, now deployed for Absci’s AI drug discovery platform in service of our mission to accelerate AI antibody design and discovery.

View post on LinkedIn

Absci 1w ago

Our Founder and CEO, Sean McClain, recently sat down with actor and health content creator Philipp Karner to discuss ABS-201, an investigational treatment for pattern hair loss currently in a Phase 1/2a clinical trial. In this episode, Sean explains ABS-201's novel prolactin mechanism, diving into the preclinical science and interim Phase 1 data. 📍Watch the full conversation: https://lnkd.in/gt-ZUnqN

View post on LinkedIn

Absci 1w ago

Our ABS-201 program for pattern hair loss was recently featured in Bustle, covering the opening of a dedicated women’s cohort in our Phase 1/2a clinical trial. Pattern hair loss affects millions of women, yet treatment options remain limited. Absci is working to rapidly advance ABS-201, our AI-designed anti-PRLR antibody, which has the potential to introduce the first new mechanism of action for androgenetic alopecia in nearly three decades. Read the article: https://lnkd.in/gTE6cfyA 🦲Learn more about HEADLINE: https://headlinetrial.com/

View post on LinkedIn